Designing transformative therapeutics by integrating frontier AI with autonomous generation of gold standard data.

Mission

Our Milliner^TM platform is a high-throughput data-generation engine, connecting computational design with automated experimentation to generate the high-integrity biological data needed to train, evaluate and improve AI models.

01.

Full-stack antibody discovery and engineering

BigHat’s Milliner platform combines a high-throughput, automated wet lab with a custom AI harness that orchestrates a diverse set of computational models, enabling the company to design and evaluate thousands of antibodies each week and simultaneously optimize multiple properties critical to therapeutic development.

02.

Better Antibodies Faster

Better antibodies faster

Thousands of recombinant antibodies can be synthesized, purified, and fully characterized in a single weekly workcell.

03.

For Today’s Most Challenging Diseases

For today’s most challenging diseases

Antibodies are some of the most powerful and successful medicines for diseases from infections to cancers. They are poised to benefit from next generation AI-enabled design, with a goal of providing greater safety and efficacy for patients with rational molecular design.

company

Who we are

At BigHat, we have a high-performance culture of excellence, but also pride ourselves on our work/life balance and family-friendly culture.

We’re a clinical-stage biotech in San Mateo, CA, with wholly-owned and partnered programs. We’ve raised >$100M from top investors to pursue our vision to create the future of AI-native drug discovery.

Learn more about BigHat